Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis-Reference-Cited by-同舟云学术

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis

Published:2014-04-27 Issue:1 Volume:14 Page:
ISSN:1472-6963
Container-title:BMC Health Services Research
language:en
Short-container-title:BMC Health Serv Res

Author:

Weycker Derek,Barron Rich,Edelsberg John,Kartashov Alex,Legg Jason,Glass Andrew G

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Link

http://link.springer.com/article/10.1186/1472-6963-14-189/fulltext.html

Reference30 articles.

1. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT: Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005, 103: 1916-1924. 10.1002/cncr.20983.

2. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006, 24 (19): 3187-3205. 10.1200/JCO.2006.06.4451.

3. Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J: Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010, 116 (23): 5555-5563. 10.1002/cncr.25332.

4. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006, 106: 2258-2266. 10.1002/cncr.21847.

5. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P: 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005, 330 (7485): 217-10.1136/bmj.38314.622095.8F.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study;Journal of Modern Oncology;2024-02-21

2. Drug‐induced pneumonitis risk in diffuse large B‐cell/follicular lymphoma patients treated with R‐CHOP‐like regimen is associated with the use of granulocyte colony‐stimulating growth factors;Cancer Medicine;2024-01

3. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer;Supportive Care in Cancer;2023-09-20

4. Neutropenie – wann ist eine GCSF Unterstützung notwendig?;Aktuelle Urologie;2023-08-22

5. Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study;PLOS ONE;2023-07-17